Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Paracrine Proangiogenic Function of Human Bone Marrow-Derived Mesenchymal Stem Cells Is Not Affected by Chronic Kidney Disease.

van Rhijn-Brouwer FCC, van Balkom BWM, Papazova DA, Hazenbrink DHM, Meijer AJ, Brete I, Briceno V, van Zuilen AD, Toorop RJ, Fledderus JO, Gremmels H, Verhaar MC.

Stem Cells Int. 2019 Dec 23;2019:1232810. doi: 10.1155/2019/1232810. eCollection 2019.

2.

Exhaustion of the bone marrow progenitor cell reserve is associated with major events in severe limb ischemia.

Gremmels H, van Rhijn-Brouwer FCC, Papazova DA, Fledderus JO, Teraa M, Verhaar MC; JUVENTAS study group.

Angiogenesis. 2019 Aug;22(3):411-420. doi: 10.1007/s10456-019-09666-0. Epub 2019 Mar 30.

3.

Characterization of Endothelial and Smooth Muscle Cells From Different Canine Vessels.

Oosterhoff LA, Kruitwagen HS, van Wolferen ME, van Balkom BWM, Mokry M, Lansu N, van den Dungen NAM, Penning LC, Spanjersberg TCF, de Graaf JW, Veenendaal T, Zomerdijk F, Fledderus JO, Spee B, van Steenbeek FG.

Front Physiol. 2019 Feb 12;10:101. doi: 10.3389/fphys.2019.00101. eCollection 2019.

4.

Effect of donor variation on osteogenesis and vasculogenesis in hydrogel cocultures.

Pennings I, van Dijk LA, van Huuksloot J, Fledderus JO, Schepers K, Braat AK, Hsiao EC, Barruet E, Morales BM, Verhaar MC, Rosenberg AJWP, Gawlitta D.

J Tissue Eng Regen Med. 2019 Mar;13(3):433-445. doi: 10.1002/term.2807. Epub 2019 Feb 8.

5.

A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol.

van Rhijn-Brouwer FCC, Gremmels H, Fledderus JO, Schuurman AH, Bonte-Mineur F, Vonk MC, Voskuyl AE, de Vries-Bouwstra JK, Coert JH, Radstake TRDJ, van Laar JM, Verhaar MC; MANUS Study Group.

BMJ Open. 2018 Aug 20;8(8):e020479. doi: 10.1136/bmjopen-2017-020479.

6.

Mesenchymal Stromal Cell Characteristics and Regenerative Potential in Cardiovascular Disease: Implications for Cellular Therapy.

van Rhijn-Brouwer FCC, Gremmels H, Fledderus JO, Verhaar MC.

Cell Transplant. 2018 May;27(5):765-785. doi: 10.1177/0963689717738257. Epub 2018 Jun 13. Review.

7.

The Transcription Factor Nrf2 Protects Angiogenic Capacity of Endothelial Colony-Forming Cells in High-Oxygen Radical Stress Conditions.

Gremmels H, de Jong OG, Hazenbrink DH, Fledderus JO, Verhaar MC.

Stem Cells Int. 2017;2017:4680612. doi: 10.1155/2017/4680612. Epub 2017 May 15.

8.

Cellular Therapies in Systemic Sclerosis: Recent Progress.

van Rhijn-Brouwer FC, Gremmels H, Fledderus JO, Radstake TR, Verhaar MC, van Laar JM.

Curr Rheumatol Rep. 2016 Feb;18(2):12. doi: 10.1007/s11926-015-0555-7. Review.

9.

Early in-situ cellularization of a supramolecular vascular graft is modified by synthetic stromal cell-derived factor-1α derived peptides.

Muylaert DE, van Almen GC, Talacua H, Fledderus JO, Kluin J, Hendrikse SI, van Dongen JL, Sijbesma E, Bosman AW, Mes T, Thakkar SH, Smits AI, Bouten CV, Dankers PY, Verhaar MC.

Biomaterials. 2016 Jan;76:187-95. doi: 10.1016/j.biomaterials.2015.10.052. Epub 2015 Oct 23.

PMID:
26524538
10.

Environmental Influences on Endothelial to Mesenchymal Transition in Developing Implanted Cardiovascular Tissue-Engineered Grafts.

Muylaert DEP, de Jong OG, Slaats GGG, Nieuweboer FE, Fledderus JO, Goumans MJ, Hierck BP, Verhaar MC.

Tissue Eng Part B Rev. 2016 Feb;22(1):58-67. doi: 10.1089/ten.TEB.2015.0167. Epub 2015 Oct 8.

PMID:
26414174
11.

Lymphatic Vascular Regeneration: The Next Step in Tissue Engineering.

Huethorst E, Krebber MM, Fledderus JO, Gremmels H, Xu YJ, Pei J, Verhaar MC, Cheng C.

Tissue Eng Part B Rev. 2016 Feb;22(1):1-14. doi: 10.1089/ten.TEB.2015.0231. Epub 2015 Nov 18.

PMID:
26204330
12.

Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease.

van Koppen A, Papazova DA, Oosterhuis NR, Gremmels H, Giles RH, Fledderus JO, Joles JA, Verhaar MC.

Stem Cell Res Ther. 2015 Apr 15;6:63. doi: 10.1186/s13287-015-0064-7.

13.

Tissue engineering for human urethral reconstruction: systematic review of recent literature.

de Kemp V, de Graaf P, Fledderus JO, Ruud Bosch JL, de Kort LM.

PLoS One. 2015 Feb 17;10(2):e0118653. doi: 10.1371/journal.pone.0118653. eCollection 2015. Review.

14.

Oleic acid increases mitochondrial reactive oxygen species production and decreases endothelial nitric oxide synthase activity in cultured endothelial cells.

Gremmels H, Bevers LM, Fledderus JO, Braam B, van Zonneveld AJ, Verhaar MC, Joles JA.

Eur J Pharmacol. 2015 Mar 15;751:67-72. doi: 10.1016/j.ejphar.2015.01.005. Epub 2015 Jan 13.

PMID:
25595727
15.

Letter regarding the article, "a detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes".

Gremmels H, Papazova DA, Fledderus JO, Verhaar MC.

Circ Res. 2014 Dec 5;115(12):e35. doi: 10.1161/CIRCRESAHA.114.305312. No abstract available.

PMID:
25477486
16.

Different types of cultured human adult cardiac progenitor cells have a high degree of transcriptome similarity.

Gaetani R, Feyen DA, Doevendans PA, Gremmels H, Forte E, Fledderus JO, Ramjankhan FZ, Messina E, Sussman MA, Giacomello A, Sluijter JP.

J Cell Mol Med. 2014 Nov;18(11):2147-51. doi: 10.1111/jcmm.12458. Epub 2014 Oct 14. No abstract available.

17.

Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls.

Gremmels H, Teraa M, Quax PH, den Ouden K, Fledderus JO, Verhaar MC.

Mol Ther. 2014 Nov;22(11):1960-70. doi: 10.1038/mt.2014.161. Epub 2014 Sep 1.

18.

Combining tissue repair and tissue engineering; bioactivating implantable cell-free vascular scaffolds.

Muylaert DE, Fledderus JO, Bouten CV, Dankers PY, Verhaar MC.

Heart. 2014 Dec;100(23):1825-30. doi: 10.1136/heartjnl-2014-306092. Epub 2014 Jul 22. Review.

PMID:
25053725
19.

Prolonged presence of VEGF promotes vascularization in 3D bioprinted scaffolds with defined architecture.

Poldervaart MT, Gremmels H, van Deventer K, Fledderus JO, Oner FC, Verhaar MC, Dhert WJ, Alblas J.

J Control Release. 2014 Jun 28;184:58-66. doi: 10.1016/j.jconrel.2014.04.007. Epub 2014 Apr 13.

PMID:
24727077
20.

Beneficial effects of diminished production of hydrogen sulfide or carbon monoxide on hypertension and renal injury induced by NO withdrawal.

Wesseling S, Fledderus JO, Verhaar MC, Joles JA.

Br J Pharmacol. 2015 Mar;172(6):1607-19. doi: 10.1111/bph.12674. Epub 2014 Jul 2.

21.

Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective.

Gremmels H, Fledderus JO, Teraa M, Verhaar MC.

Stem Cell Res Ther. 2013;4(6):140.

22.

Bone marrow microvascular and neuropathic alterations in patients with critical limb ischemia.

Teraa M, Fledderus JO, Rozbeh RI, Leguit RJ, Verhaar MC; Juventas Study Group{dagger}.

Circ Res. 2014 Jan 17;114(2):311-4. doi: 10.1161/CIRCRESAHA.114.302791. Epub 2013 Nov 11.

PMID:
24218170
23.

Matrix production and organization by endothelial colony forming cells in mechanically strained engineered tissue constructs.

de Jonge N, Muylaert DE, Fioretta ES, Baaijens FP, Fledderus JO, Verhaar MC, Bouten CV.

PLoS One. 2013 Sep 2;8(9):e73161. doi: 10.1371/journal.pone.0073161. eCollection 2013.

24.

Nrf2 implicated as a novel therapeutic target for renal regeneration after acute kidney injury.

Fledderus JO, Goldschmeding R.

Nephrol Dial Transplant. 2013 Aug;28(8):1969-71. doi: 10.1093/ndt/gft202. No abstract available.

PMID:
24014316
25.

Increased amount of bone marrow-derived smooth muscle-like cells and accelerated atherosclerosis in diabetic apoE-deficient mice.

Fledderus JO, van Oostrom O, de Kleijn DP, den Ouden K, Penders AF, Gremmels H, de Bree P, Verhaar MC.

Atherosclerosis. 2013 Feb;226(2):341-7. doi: 10.1016/j.atherosclerosis.2012.11.017. Epub 2012 Nov 23.

26.

Polymer-based scaffold designs for in situ vascular tissue engineering: controlling recruitment and differentiation behavior of endothelial colony forming cells.

Fioretta ES, Fledderus JO, Burakowska-Meise EA, Baaijens FP, Verhaar MC, Bouten CV.

Macromol Biosci. 2012 May;12(5):577-90. doi: 10.1002/mabi.201100315. Epub 2012 Jan 25. Review.

PMID:
22566363
27.

Comment on 'Stem-cell therapy for peripheral arterial occlusive disease'.

Teraa M, Verhaar MC, Gremmels H, Fledderus JO, Schutgens RE, Moll FL.

Eur J Vasc Endovasc Surg. 2012 Apr;43(4):486; author reply 487. doi: 10.1016/j.ejvs.2012.01.010. Epub 2012 Jan 28. No abstract available.

28.

Influence of substrate stiffness on circulating progenitor cell fate.

Fioretta ES, Fledderus JO, Baaijens FP, Bouten CV.

J Biomech. 2012 Mar 15;45(5):736-44. doi: 10.1016/j.jbiomech.2011.11.013. Epub 2011 Dec 9.

PMID:
22169135
29.

Expanding the beneficial pleiotropic repertoire of interleukin-10.

Fledderus JO, Joles JA.

J Hypertens. 2011 Nov;29(11):2061-3. doi: 10.1097/HJH.0b013e32834c3041. No abstract available.

PMID:
21989379
30.

Hypoxia impedes vasculogenesis of in vitro engineered bone.

Gawlitta D, Fledderus JO, van Rijen MH, Dokter I, Alblas J, Verhaar MC, Dhert WJ.

Tissue Eng Part A. 2012 Jan;18(1-2):208-18. doi: 10.1089/ten.TEA.2010.0731. Epub 2011 Oct 4.

31.

Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis.

van der Laan AM, Schirmer SH, de Vries MR, Koning JJ, Volger OL, Fledderus JO, Bastiaansen AJ, Hollander MR, Baggen JM, Koch KT, Baan J Jr, Henriques JP, van der Schaaf RJ, Vis MM, Mebius RE, van der Pouw Kraan TC, Quax PH, Piek JJ, Horrevoets AJ, van Royen N.

Eur Heart J. 2012 May;33(9):1076-84. doi: 10.1093/eurheartj/ehr220. Epub 2011 Aug 10.

PMID:
21831908
32.

Activin A induces a non-fibrotic phenotype in smooth muscle cells in contrast to TGF-β.

Groenendijk BC, Benus GF, Klous A, Pacheco YM, Volger OL, Fledderus JO, Ferreira V, Engelse MA, Pannekoek H, ten Dijke P, Horrevoets AJ, de Vries CJ.

Exp Cell Res. 2011 Jan 15;317(2):131-42. doi: 10.1016/j.yexcr.2010.10.007. Epub 2010 Oct 15.

PMID:
20955695
33.

Transcriptome analysis in endothelial progenitor cell biology.

Gremmels H, Fledderus JO, van Balkom BW, Verhaar MC.

Antioxid Redox Signal. 2011 Aug 15;15(4):1029-42. doi: 10.1089/ars.2010.3594. Epub 2011 Feb 14. Review.

PMID:
20812873
34.

Blocking interferon {beta} stimulates vascular smooth muscle cell proliferation and arteriogenesis.

Schirmer SH, Bot PT, Fledderus JO, van der Laan AM, Volger OL, Laufs U, Böhm M, de Vries CJ, Horrevoets AJ, Piek JJ, Hoefer IE, van Royen N.

J Biol Chem. 2010 Nov 5;285(45):34677-85. doi: 10.1074/jbc.M110.164350. Epub 2010 Aug 24.

35.

Expression of a retinoic acid signature in circulating CD34 cells from coronary artery disease patients.

van der Pouw Kraan TC, Schirmer SH, Fledderus JO, Moerland PD, Baggen JM, Leyen TA, van der Laan AM, Piek JJ, van Royen N, Horrevoets AJ.

BMC Genomics. 2010 Jun 21;11:388. doi: 10.1186/1471-2164-11-388.

36.

KLF2-induced actin shear fibers control both alignment to flow and JNK signaling in vascular endothelium.

Boon RA, Leyen TA, Fontijn RD, Fledderus JO, Baggen JM, Volger OL, van Nieuw Amerongen GP, Horrevoets AJ.

Blood. 2010 Mar 25;115(12):2533-42. doi: 10.1182/blood-2009-06-228726. Epub 2009 Dec 23.

PMID:
20032497
37.

Folic acid supplementation normalizes the endothelial progenitor cell transcriptome of patients with type 1 diabetes: a case-control pilot study.

van Oostrom O, de Kleijn DP, Fledderus JO, Pescatori M, Stubbs A, Tuinenburg A, Lim SK, Verhaar MC.

Cardiovasc Diabetol. 2009 Aug 25;8:47. doi: 10.1186/1475-2840-8-47.

38.

Local cytokine concentrations and oxygen pressure are related to maturation of the collateral circulation in humans.

Schirmer SH, van Royen N, Moerland PD, Fledderus JO, Henriques JP, van der Schaaf RJ, Vis MM, Baan J Jr, Koch KT, Horrevoets AJ, Hoefer IE, Piek JJ.

J Am Coll Cardiol. 2009 Jun 9;53(23):2141-7. doi: 10.1016/j.jacc.2009.02.049.

39.

Smooth muscle progenitor cells: friend or foe in vascular disease?

van Oostrom O, Fledderus JO, de Kleijn D, Pasterkamp G, Verhaar MC.

Curr Stem Cell Res Ther. 2009 May;4(2):131-40. Review.

40.

Suppression of inflammatory signaling in monocytes from patients with coronary artery disease.

Schirmer SH, Fledderus JO, van der Laan AM, van der Pouw-Kraan TC, Moerland PD, Volger OL, Baggen JM, Böhm M, Piek JJ, Horrevoets AJ, van Royen N.

J Mol Cell Cardiol. 2009 Feb;46(2):177-85. doi: 10.1016/j.yjmcc.2008.10.029. Epub 2008 Nov 14.

PMID:
19059264
41.

KLF2 primes the antioxidant transcription factor Nrf2 for activation in endothelial cells.

Fledderus JO, Boon RA, Volger OL, Hurttila H, Ylä-Herttuala S, Pannekoek H, Levonen AL, Horrevoets AJ.

Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1339-46. doi: 10.1161/ATVBAHA.108.165811. Epub 2008 May 8.

PMID:
18467642
42.

Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice.

Schirmer SH, Fledderus JO, Bot PT, Moerland PD, Hoefer IE, Baan J Jr, Henriques JP, van der Schaaf RJ, Vis MM, Horrevoets AJ, Piek JJ, van Royen N.

Circ Res. 2008 May 23;102(10):1286-94. doi: 10.1161/CIRCRESAHA.108.171827. Epub 2008 Apr 17.

PMID:
18420941
43.

SOX-18 controls endothelial-specific claudin-5 gene expression and barrier function.

Fontijn RD, Volger OL, Fledderus JO, Reijerkerk A, de Vries HE, Horrevoets AJ.

Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H891-900. Epub 2007 Dec 7.

44.

Distinctive expression of chemokines and transforming growth factor-beta signaling in human arterial endothelium during atherosclerosis.

Volger OL, Fledderus JO, Kisters N, Fontijn RD, Moerland PD, Kuiper J, van Berkel TJ, Bijnens AP, Daemen MJ, Pannekoek H, Horrevoets AJ.

Am J Pathol. 2007 Jul;171(1):326-37.

45.

Prolonged shear stress and KLF2 suppress constitutive proinflammatory transcription through inhibition of ATF2.

Fledderus JO, van Thienen JV, Boon RA, Dekker RJ, Rohlena J, Volger OL, Bijnens AP, Daemen MJ, Kuiper J, van Berkel TJ, Pannekoek H, Horrevoets AJ.

Blood. 2007 May 15;109(10):4249-57. Epub 2007 Jan 23.

PMID:
17244683
46.

KLF2 suppresses TGF-beta signaling in endothelium through induction of Smad7 and inhibition of AP-1.

Boon RA, Fledderus JO, Volger OL, van Wanrooij EJ, Pardali E, Weesie F, Kuiper J, Pannekoek H, ten Dijke P, Horrevoets AJ.

Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):532-9. Epub 2006 Dec 28.

PMID:
17194892
47.

Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization.

van Thienen JV, Fledderus JO, Dekker RJ, Rohlena J, van Ijzendoorn GA, Kootstra NA, Pannekoek H, Horrevoets AJ.

Cardiovasc Res. 2006 Nov 1;72(2):231-40. Epub 2006 Jul 12.

PMID:
16945356

Supplemental Content

Loading ...
Support Center